In a report released today, Suraj Kalia from Northland Securities maintained a Buy rating on Atricure (NASDAQ: ATRC), with a price target of $30. The company’s shares opened today at $30.80, close to its 52-week high of $33.01.
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 16.1% and a 60.8% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Obalon Therapeutics Inc, and Apollo Endosurgery Inc.
Currently, the analyst consensus on Atricure is a Strong Buy with an average price target of $35.25, which is a 14.4% upside from current levels. In a report released today, Canaccord Genuity also reiterated a Buy rating on the stock with a $37 price target.
.
See today’s analyst top recommended stocks >>
Based on Atricure’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $338K. In comparison, last year the company had a GAAP net loss of $6.88 million.
Based on the recent corporate insider activity of 45 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2018, Elizabeth Krell, a Director at ATRC sold 10,000 shares for a total of $228,200.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AtriCure, Inc. engages provision of treatment of atrial fibrillation and left atrial appendage. It operates through the following geographical segments: United States, Europe, Asia, and Other International.
